Cancer Research UK Cambridge Institute

Cancer Research UK Cambridge Institute
Name	Cancer Research UK Cambridge Institute
Established	2007
Director	Greg Hannon
Parent organization	Cancer Research UK
Affiliation	University of Cambridge
Location	Cambridge, England, United Kingdom

Cancer Research UK Cambridge Institute. It is a world-leading cancer research centre, established as part of a major strategic investment by Cancer Research UK. The institute is embedded within the University of Cambridge and is situated on the Cambridge Biomedical Campus, a hub for biomedical science. Its mission is to take the latest scientific discoveries from the laboratory bench and translate them into benefits for patients, working closely with Addenbrooke's Hospital.

History and establishment

The institute was formally opened in 2007 following a £50 million commitment from Cancer Research UK, one of the largest single investments in the charity's history. It was established to create a dedicated, state-of-the-art facility for translational cancer research within the ecosystem of the University of Cambridge. The founding director was Bruce Ponder, a renowned cancer geneticist, who played a pivotal role in its creation and early vision. The building was officially opened by Her Majesty The Queen and The Duke of Edinburgh in 2007, marking its significance within the UK's research landscape.

Research focus and programmes

Research is organized around interdisciplinary programmes that bridge basic biology and clinical application. A core focus is on understanding the genetic and molecular basis of cancer, utilizing advanced techniques in genomics, single-cell analysis, and computational biology. Major programmes include research into cancer metabolism, tumour microenvironment, and early detection. The institute places a strong emphasis on translational projects, aiming to develop new diagnostics and therapies, with significant work in areas such as liquid biopsies and immunotherapy.

Facilities and resources

Housed in a purpose-built facility on the Cambridge Biomedical Campus, the institute provides researchers with cutting-edge technology platforms. These core facilities include next-generation DNA sequencing, advanced microscopy, proteomics, and a state-of-the-art bioinformatics unit. The building is designed to foster collaboration, with open-plan laboratories and shared spaces. Its immediate proximity to Addenbrooke's Hospital and the University of Cambridge School of Clinical Medicine is integral to its translational model, facilitating direct access to clinical samples and expertise.

Key scientific contributions

Scientists have made numerous high-impact contributions to cancer research. Pioneering work in cancer genomics has defined the genetic landscapes of several cancer types, including breast cancer and renal cell carcinoma. Research led by Greg Hannon has been instrumental in advancing RNA interference technology and understanding tumour heterogeneity. The institute has also been at the forefront of developing non-invasive liquid biopsy methods for cancer detection and monitoring, published in leading journals like *Nature* and *Science*.

Collaborations and partnerships

Collaboration is central to its model, with extensive networks spanning academia, healthcare, and industry. It maintains deep strategic ties with the University of Cambridge, particularly the Department of Oncology and the Wellcome Sanger Institute. It is a key partner in the Cambridge Cancer Centre, a virtual alliance of cancer researchers across the city. Further collaborations include the Early Cancer Institute and international consortia such as the International Cancer Genome Consortium. Partnerships with pharmaceutical companies like AstraZeneca help accelerate the development of new therapies.

Organisation and leadership

The institute is a core-funded component of Cancer Research UK but operates as an integral department within the University of Cambridge. It is led by a Director, a position held since 2016 by Greg Hannon, a Royal Society Fellow and former Howard Hughes Medical Institute investigator. Research is conducted by interdisciplinary teams led by group leaders, who are principal investigators holding faculty positions at the University of Cambridge. The institute's governance involves a scientific advisory board comprising international leaders in cancer research.

Category:Research institutes in Cambridge Category:Cancer research organizations Category:University of Cambridge